Ascepion Pharmaceuticals (China)

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

• Immunology and Microbiology 5.0×
• Medicine 4.1×
• Biochemistry, Genetics and Molecular Biology 2.2×
• Engineering 0.3×

By volume in 2022–2025: HER2/EGFR in Cancer Research, Chemokine receptors and signaling, Radiopharmaceutical Chemistry and Applications and Nanoplatforms for cancer theranostics.

1. 1 HER2/EGFR in Cancer Research Oncology 2 works
2. 2 Chemokine receptors and signaling Oncology 1 works
3. 3 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
4. 4 Nanoplatforms for cancer theranostics Biomedical Engineering 0 works
5. 5 Cell Adhesion Molecules Research Immunology and Allergy 0 works
6. 6 Cancer Immunotherapy and Biomarkers Oncology 0 works
7. 7 Medical Imaging Techniques and Applications Radiology, Nuclear Medicine and Imaging 0 works
8. 8 Cancer Treatment and Pharmacology Oncology 0 works
9. 9 Inflammatory mediators and NSAID effects Pharmacology 0 works
10. 10 Angiogenesis and VEGF in Cancer Molecular Biology 0 works

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

Output in 2018–2022 was 3276% higher than in 2013–2017.

• Soochow University
• Suzhou University of Science and Technology
• Xi’an Jiaotong-Liverpool University
• First Affiliated Hospital of Soochow University
• Suzhou Research Institute
• Second Affiliated Hospital of Soochow University
• Suzhou Institute of Nano-tech and Nano-bionics
• Suzhou Vocational University